Unilateral GPi vs Unilateral STN DBS in the Same Patient With PD

Parkinson Disease Clinical Trial

Official title:

Unilateral Pallidal vs Unilateral Subthalamic Nucleus Deep Brain Stimulation in the Same Patient With Parkinson Disease: A Randomized Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04255719
• Other study ID #: 2020 UPS study
• Status: Completed
• Phase: N/A
• Start date: March 1, 2020
• Est. completion date: March 2, 2021

Study information

• Verified date: March 2021
• Source: Ruijin Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The subthalamic nucleus (STN) and globus pallidus interna (GPi) are two main targets in the deep brain stimulation (DBS) treatment for Parkinson's disease (PD). Large randomized controlled trials, in which patients of comparable clinical and demographics were randomized to either GPi DBS or STN DBS, have demonstrated equal effects of both targets in motor symptom improvement, the superiority of STN DBS in the medication reduction and the potential advantage of GPi DBS for cognitive, psychiatric and axial aspects. Unfortunately, in such a highly heterogeneous disease of PD, many of these randomized controlled trials didn't include sufficient subjects and thereby yielded inconsistent results. Moreover, most studies are investigating the difference between GPi and STN in different patients. In order to address the problem, an intra-patient comparison will be made by investigating the acute turning-on effects of unilateral STN stimulation versus unilateral GPi stimulation on axial symptoms, cognition and also cardinal symptoms within each individual patient who received the treatment of combined unilateral STN and contralateral GPi DBS. Axial symptoms including gait, balance and posture, motor symptoms and cognition are comprehensively assessed under two treatment conditions.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9
• Est. completion date: March 2, 2021
• Est. primary completion date: February 27, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 55 Years to 75 Years

Eligibility

Inclusion Criteria:

• Patients with idiopathic Parkinson's disease
• Aged between 55 and 75 years, both male and female
• Patients who have undergone combined unilateral STN and contralateral GPi DBS for more than 6 months
• A Hoehn-Yahr (H-Y) stage of less than 4 in the off-medication state
• A left-extremity to right-extremity ratio of less than 0.15 on the Unified Parkinson's Disease Rating Scale part ? (UPDRS-?) in the both off-medication and on-medication states

Exclusion Criteria:

• History of serious psychosis
• History of intractable epilepsy (i.e., seizures)
• Diagnosed by the investigators that patients with severe cardiac, liver and kidney diseases, or other serious health conditions
• Dementia (A Mini-Mental State Examination (MMSE) score of < 24), inability to comprehend the experimental protocol or voluntarily provide informed consent
• Lack of cooperation
• Additional reasons for exclusion at the discretion of the clinical investigator
• Poorly controlled depression or anxiety
• Past history of suicidal attempt

Related Conditions & MeSH terms

• Deep Brain Stimulation
• Globus Pallidus Interna
• Parkinson Disease
• Subthalamic Nucleus

Intervention

Procedure:
• DBS
Unilateral DBS for treatment of patients with PD

Locations

Country	Name	City	State
China	Functional neurosurgery of Shanghai jiaotong university affiliated Ruijin hospital	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Ruijin Hospital

Country where clinical trial is conducted

China, 

References & Publications (2)

Lizarraga KJ, Luca CC, De Salles A, Gorgulho A, Lang AE, Fasano A. Asymmetric neuromodulation of motor circuits in Parkinson's disease: The role of subthalamic deep brain stimulation. Surg Neurol Int. 2017 Oct 24;8:261. doi: 10.4103/sni.sni_292_17. eCollection 2017. Review. — View Citation

Yamada K, Shinojima N, Hamasaki T, Kuratsu J. Subthalamic nucleus stimulation improves Parkinson's disease-associated camptocormia in parallel to its preoperative levodopa responsiveness. J Neurol Neurosurg Psychiatry. 2016 Jul;87(7):703-9. doi: 10.1136/jnnp-2015-310926. Epub 2015 Sep 30. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Difference in Timed Up-and-Go (TUG) task scores between treatment conditions in the on- and off- medication states	Timed Up-and-Go task is a well-defined objective gait measurement. The task requires an individual to stand up, walk 5 m, turn, walk back, and sit down. The time taken to complete the test is strongly correlated with the level of functional mobility. This test will be videotaped and scored by two blinded neurologists.	6 months
Secondary	Differences in total Uni?ed Parkinson's Disease Rating Scale Part ? (UPDRS ?) scores between two treatment conditions in the on- and off- medication states	Uni?ed Parkinson's Disease Rating Scale Part ? measures the motor severity of Parkinson's disease. UPDRS ? score has a range of 0 (no symptoms) to 132 (severe disease symptoms).	6 months
Secondary	Differences in Burg Balance Scale (BBS) scores between two treatment conditions in the on- and off- medication states.	Burg Balance Scale measures patients' static and dynamic balance abilities. BBS score has a range of 0 (severe balance problems) to 56 (no balance problems).	6 months
Secondary	Differences in postural angles between two treatment conditions in the on- and off- medication states.	The measurement of postural angles is the same as the paper (Yamada et al) published in J Neurol Neurosurg Psychiatry	6 months
Secondary	Differences in Water Swallow Test (WST) scores between treatment conditions in the on- and off- medication states.	The Water Swallow Test is frequently used in clinical practice as a functional assessment to detect dysphagia, with stage 1 indicating severe dysphagia and stage 6 indicating normal swallowing function.	6 months
Secondary	Differences in Swallowing Disturbance Questionnaire (SDQ) scores between treatment conditions in the on- and off- medication states.	The Swallowing Disturbance Questionnaire is created as a self-rated dysphagia screening tool in PD, with a range of 0 (normal swallowing function) to 42 (severe dysphagia).	6 months
Secondary	Differences in voice parameters between treatment conditions in the on- and off- medication states.	Voice recording at a sampling rate of 44.1 kHz using 16-bit quantification will be conducted in a sound-treated room using a microphone and a digital voice recorder with a mouth-to-microphone distance of 15 cm. The recorded voices will then be used for a composit acoustic analysis.	6 months
Secondary	Differences in Voice Handicap Index (VHI) between treatment conditions in the on- and off- medication states.	The Voice Handicap Index is a self-administered instrument, comprising 30 items on voice-related dysfunction. VHI has a range of 0 (normal voice function) to 120 (severe voice dysfunction).	6 months